Risk Factors Update Summary
- Accumulated deficit increased from $237 million to $334 million, impacting financial stability.
- Proceeds from IPO and offering may not be enough to fund operations into Q1 2025.
- FDA and EU regulatory changes could impact product development timelines and approvals.
- Loan repayment extended from September 30, 2025, to September 30, 2027, with a further extension to September 30, 2028.
- Market conditions can affect cash accessibility due to deposits exceeding insured limits.
- New regulations may increase data breach litigation risks and compliance costs.
- Uncertainty around UK regulations alignment with EU may impact clinical trials and approvals.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1850838&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.